MTCH
48
11
PNC
53
-2
NEM
46
-2
VZ
39
2
MUR
34
-10
FOXA
60
-3
FTI
76
3
MHK
31
-3
XRAY
47
-2
VTR
43
-3
AAPL
64
11
GT
56
-2
ZION
57
-3
INTU
59
-3
HUM
33
2
RSG
62
-2
AVGO
88
27
NDAQ
50
-6
PEG
55
2
AKAM
59
-2
MTCH
48
11
PNC
53
-2
NEM
46
-2
VZ
39
2
MUR
34
-10
FOXA
60
-3
FTI
76
3
MHK
31
-3
XRAY
47
-2
VTR
43
-3
AAPL
64
11
GT
56
-2
ZION
57
-3
INTU
59
-3
HUM
33
2
RSG
62
-2
AVGO
88
27
NDAQ
50
-6
PEG
55
2
AKAM
59
-2
Financhill
Back

Keros Therapeutics Quote, Financials, Valuation and Earnings

The dark truth about AI

Click here to learn more...
Sell
15

KROS
Keros Therapeutics

Last Price:
18.85
Seasonality Move:
14.46%

7 Day Trial

ALL ACCESS PASS

$ 7

Zero Day Options Trade LIVE Tuesday at 2 p.m. ET!

Discover The Zero Day Loophole (BEFORE Tues at 2 p.m. ET!)

Keros Therapeutics Price Quote

$18.85
+0.02 (+2.28%)
(Updated: December 14, 2024 at 5:40 AM ET)

Keros Therapeutics Key Stats

Sell
15
Keros Therapeutics (KROS) is a Sell
Day range:
$17.52 - $21.05
52-week range:
$15.67 - $73.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
987.42
P/B ratio:
1.4%
Volume:
5.1M
Avg. volume:
1.1M
1-year change:
-37.88%
Market cap:
$746.6M
Revenue:
$151K
EPS:
$-5.21

How Much Does Keros Therapeutics Make?

Is Keros Therapeutics Growing As A Company?

  • What Is Keros Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 47.5%
  • What Is Keros Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Keros Therapeutics Stock Price Performance

What Is Keros Therapeutics 52-Week High & Low?

Keros Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Keros Therapeutics?

Is Keros Therapeutics Cash Flow Positive?

  • What Is KROS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$140.3M
  • What Is Keros Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $385.5M
  • What Is Keros Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$2.2M

Keros Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    KROS return on invested capital is -44.6%
  • What Is Keros Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -40.96%
  • What Is KROS Return On Equity?
    ROE is a measure of profitability and is -44.6%

Keros Therapeutics Earnings Date & Stock Price

Keros Therapeutics Competitors

  • Who Are Keros Therapeutics's Competitors?
    Below is a list of companies who compete with Keros Therapeutics or are related in some way:
    • Eli Lilly and Co (LLY)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Regeneron Pharmaceuticals Inc (REGN)
    • Scholar Rock Holding Corp (SRRK)

Keros Therapeutics Dividend Yield

Keros Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -10.52%
Revenue: 4750% 0%

Analyst Recommendations

Buy Recommendations: 9
Hold Recommendations: 3
Sell Recommendations: 0
Price Target: 88.08
Upside from Last Price: 367.78%

Major Shareholders

  • How many KROS shares are owned by institutional investors?
    52.9M KROS shares are owned by institutional investors
  • How many KROS shares are owned by insiders?
    372.4K KROS shares are owned by insiders